Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05603182 · ClinicalTrials.gov registry record · Phase 1
A Study of PRA052 in Healthy Volunteers
A Phase 1 study, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT05603182 is a Phase 1 study that has completed, run by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 96 participants.
The verdict
NCT05603182, a Phase 1 study, has completed, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This is randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA052 in healthy volunteers.
Interventions
- OTHER Placebo
- DRUG PRA052
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 1 |
Sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05603182
The ClinicalTrials.gov registry entry for NCT05603182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05603182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05603182 about?
NCT05603182 is a clinical study titled "A Study of PRA052 in Healthy Volunteers". This is randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA052 in healthy volunteers.
What is the current status of trial NCT05603182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2022-11-07. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT05603182?
The interventions under investigation include: Placebo (OTHER), PRA052 (DRUG).
Who is sponsoring clinical trial NCT05603182?
This trial is sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.